Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2008

01-05-2008 | Poster presentation

Chemotherapy-induced modulation of [18F]Fluoro-2-deoxy-D-glucose incorporation at the tumour cell level

Authors: RI Sharma, RW Cheyne, SA Suttie, TAD Smith

Published in: Breast Cancer Research | Special Issue 2/2008

Login to get access

Excerpt

Changes in the incorporation of [18F]Fluoro-2-deoxy-D-glucose (FDG) determined using positron emission tomography (PET) is a highly sensitive technique for the early detection of tumour response to therapy [1]. Using serial FDG-PET scans, tumours responding to therapy generally show a decrease in FDG incorporation compared with pretreatment. How FDG incorporation at the tumour cell level is modified by treatment and the mechanisms involved is poorly understood and is the subject of the present study. …
Literature
1.
Weber WA, Figlin R: Monitoring cancer treatment with PET/CT: does it make a difference?. J Nucl Med. 2007, 48: 36S-44S. 10.2967/jnumed.107.042911.CrossRefPubMed
Metadata
Title
Chemotherapy-induced modulation of [18F]Fluoro-2-deoxy-D-glucose incorporation at the tumour cell level
Authors
RI Sharma
RW Cheyne
SA Suttie
TAD Smith
Publication date
01-05-2008
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2008
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1952

Other articles of this Special Issue 2/2008

Breast Cancer Research 2/2008 Go to the issue

Poster presentation

'The sooner the better' or 'too much too soon'? A pilot prospective longitudinal study to evaluate quality of life and body image following immediate latissimus dorsi breast reconstruction

Lecture presentation

Molecular diversity of human breast cancer: clinical and therapeutic implications

Poster presentation

Detection of gene amplification in matched tumour and plasma DNA from breast cancer patients by quantitative PCR

Poster presentation

Cytochrome P450 modulates the therapeutic actions of tamoxifen, as evidenced in novel breast cancer models

Poster presentation

Identification and role of migration stimulating factor isoforms in breast carcinomas

Poster presentation

Anti-oestrogen therapy switches off tumour suppressors and proapoptotic genes in breast cancer and reveals a new therapeutic opportunity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits